FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 206 filers reported holding FATE THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,869,405 | -55.4% | 185,273 | -1.3% | 0.01% | -60.0% |
| Q3 2022 | $4,192,000 | -5.6% | 187,639 | +5.1% | 0.02% | -6.2% |
| Q2 2022 | $4,442,000 | +1.0% | 178,553 | +57.5% | 0.02% | +33.3% |
| Q1 2022 | $4,396,000 | -25.6% | 113,380 | +12.3% | 0.01% | -7.7% |
| Q4 2021 | $5,905,000 | +6.4% | 100,928 | +7.8% | 0.01% | 0.0% |
| Q3 2021 | $5,549,000 | -31.3% | 93,621 | +0.5% | 0.01% | -38.1% |
| Q2 2021 | $8,082,000 | +9.6% | 93,120 | +4.1% | 0.02% | +5.0% |
| Q1 2021 | $7,373,000 | -13.9% | 89,424 | -5.1% | 0.02% | -13.0% |
| Q4 2020 | $8,565,000 | +71.2% | 94,189 | -24.8% | 0.02% | +27.8% |
| Q3 2020 | $5,004,000 | +23.9% | 125,188 | +6.3% | 0.02% | +20.0% |
| Q2 2020 | $4,039,000 | +60.3% | 117,727 | +3.7% | 0.02% | +7.1% |
| Q1 2020 | $2,520,000 | +59.7% | 113,474 | +40.7% | 0.01% | +75.0% |
| Q4 2019 | $1,578,000 | – | 80,651 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |